Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Glimepiride tablet and preparation method thereof

A technology of Glimepiride and Glimepiride, which is applied to medical formulations, sulfonylurea active ingredients, and medical preparations of non-active ingredients, etc., can solve problems such as long time required, difficult release, strong viscosity, etc., and achieve reduction Dosage, stable results, and the effect of improving hydrophilicity

Active Publication Date: 2012-06-13
CHONGQING CONQUER PHARML
View PDF2 Cites 4 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

In addition, the invention also solves the problem that traditional binders such as hypromellose take a long time to swell in water, the concentration is too high, the viscosity is too strong, and the raw material drug of glimepiride contained in it is more difficult to release. The problem of reducing the effect of drugs on the dissolution rate, improving drug dissolution and bioavailability

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Glimepiride tablet and preparation method thereof
  • Glimepiride tablet and preparation method thereof
  • Glimepiride tablet and preparation method thereof

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0018] Example 1 Preparation Method I of Glimepiride Tablets

[0019] Weigh 20g of glimepiride raw material, 360g of lactose, 100g of sodium starch glycolate, 200g of microcrystalline cellulose, 20g of microcrystalline silica gel, and 5g of magnesium stearate; prepare the glimepiride raw material by means of inert gas flow pulverization become particle size less than 2 mu m of glimepiride powder;

[0020] The glimepiride powder was mixed and ground for 90 minutes by adding lactose in increments, then mixed with microcrystalline cellulose and ground again for 30 minutes, and the grinding temperature was lower than 30°C to obtain a glimepiride-lactose mixture;

[0021] In the glimepiride-lactose mixture, carboxymethyl starch sodium and micropowder silica gel were put into the wet granulator and mixed for more than 3 minutes, and the aqueous solution containing 0.5% hypromellose by mass ratio was added to the wet granulator in a ratio of 1:20 as a binder. granulator granulati...

Embodiment 2

[0023] The preparation method II of embodiment 2 glimepiride sheet

[0024] Weigh 20g of glimepiride raw material, 360g of lactose, 100g of sodium starch glycolate, 200g of microcrystalline cellulose, 20g of microcrystalline silica gel, and 5g of magnesium stearate; prepare the glimepiride raw material by means of inert gas flow pulverization become particle size less than 2 mu m of glimepiride powder;

[0025] Glimepiride powder was mixed and ground for more than 60 minutes by adding lactose in increments, mixed with microcrystalline cellulose and ground again for more than 20 minutes, mixed with carboxymethyl starch sodium and micropowder silica gel and ground for more than 3 minutes, and the grinding temperature was lower than 30°C to obtain Glycine meurea mixture;

[0026] Add povidone dry powder into the glimepiride mixture and fully stir, mix and add magnesium stearate, control the hardness of the tablet press at 4 kg, and press the tablets to obtain glimepiride tabl...

Embodiment 3

[0027] Example 3 Preparation method I of prior art glimepiride tablets

[0028] Weigh 20g of glimepiride raw material, 360g of lactose, 100g of sodium starch glycolate, 200g of microcrystalline cellulose, 20g of microcrystalline silica gel, and 3.5g of magnesium stearate; grind and mix the glimepiride raw material with the prescribed amount of lactose After about 2 hours, the mixture was ground and mixed with microcrystalline cellulose for 30 minutes, and then mixed with the prescribed amount of sodium carboxymethyl starch and micropowder silica gel on a wet granulator for 8 minutes. Dissolve an appropriate amount of Tween 80 in 95% ethanol, then mix it with 1% hypromellose aqueous solution at a ratio of 1:20 as a binder, add it to the mixture of the wet granulator for granulation, dry it and then mix it with the prescription amount Magnesium stearate was blended and tabletted to obtain glimepiride tablets;

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
Particle sizeaaaaaaaaaa
Login to View More

Abstract

The invention discloses a Glimepiride tablet, wherein the Glimepiride tablet comprises the following components: Glimepiride tablet bulk pharmaceutical chemical, lactose, sodium starch glycolate, microcrystalline cellulose, microcrystalline silica gel and magnesium stearate at the weight ratio of (2-6):(60-90):(10-30):(10-60):(2-6):1, wherein the Glimepiride tablet bulk pharmaceutical chemical ispowder with the particle size less than 2 mu m. The invention also discloses a preparation method. With regard to Glimepiride, pharmaceuticals are smashed into particulates with the particle size less than 2mu m by an improved technology, and the hydrophilicity of the pharmaceuticals is improved; and the problem that the dissolution velocity of the pharmaceuticals is influenced is solved. Statistical analysis indicates that the average dissolution degree is above 98.5% by adopting the improved prescription and technology, and the accelerated test result for 6 months is very stable; and the research on primary pharmacokinetic parameters indicate that the preparation has the advantages of better dynamic course in human bodies and better absorption elimination properties through the checkingof statistics.

Description

technical field [0001] The invention relates to a pharmaceutical preparation, in particular to a glimepiride tablet and a preparation method thereof. technical background [0002] Glimepiride, chemical name 1-[4-[2-(3-ethyl-4-methyl-2-oxo-3-pyrroline-1-carboxamido)ethyl]benzenesulfonyl ]-3-(trans-4-methylcyclohexyl)urea, is a new sulfonylurea hypoglycemic agent, developed by the German company Hoechst Marion Roussel (HMR), first launched in Sweden under the trade name in September 1995 Amaryl was listed on the market and entered the U.S. market with FDA approval in 1996. It is used to treat type 2 diabetes that cannot be controlled by diet and exercise. It is the first sulfonylurea drug approved by the FDA that can be used simultaneously with insulin. Because the drug has a short action time with the receptor, it shortens the time for insulin secretion, so it has a strong insulin-sparing effect and can overcome the secondary failure of islet cells to a certain extent. Gl...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K9/20A61K31/64A61K47/38A61P3/10
Inventor 梅勇罗磊何远东马贵勇姜艳红
Owner CHONGQING CONQUER PHARML
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com